The DAV132 colon-targeted adsorbent does not interfere with plasma concentrations of ... - Nature
CL-006 study assessed DAV132's effect on plasma concentration of ATB (CZA, PTZ, CRO) alone or combined at 2 doses. 148 HV randomized, treated with ATB over 5 days alone or with DAV132 over 7 days. Primary objective: assess DAV132's effect on β-lactams plasma concentration. Secondary: safety, interaction on fecal β-lactam excretion. Exploratory: protective effect on intestinal microbiome diversity. Study conducted from May 2019 to Dec 2019 in France under Medical Device regulation.
Reference News
CL-006 study assessed DAV132's effect on plasma concentration of ATB (CZA, PTZ, CRO) alone or combined at 2 doses. 148 HV randomized, treated with ATB over 5 days alone or with DAV132 over 7 days. Primary objective: assess DAV132's effect on β-lactams plasma concentration. Secondary: safety, interaction on fecal β-lactam excretion. Exploratory: protective effect on intestinal microbiome diversity. Study conducted from May 2019 to Dec 2019 in France under Medical Device regulation.